What's Happening?
Roche Diagnostics is making its Endotrophin (ETP) research prototype assay available on its cobas® e801 Analyzers at Nordic Bioscience's CLIA lab. Endotrophin is a signaling pro-peptide released during the formation of type VI collagen and is associated
with fibrosis, inflammation, and adverse outcomes across cardiovascular, kidney, and metabolic diseases. This assay is a sandwich immunoassay designed to quantify the intact 77-amino-acid Endotrophin hormone. This marks the second biomarker from the collaboration between Nordic Bioscience and Roche Diagnostics to be available on the Roche platform, following the Elecsys® PRO-C3. Endotrophin has been measured in over 50,000 patients with cardio-kidney-metabolic disease, with elevated levels linked to mortality and adverse outcomes in heart failure with preserved ejection fraction (HFpEF). The FDA has issued a letter of support for continued research into Endotrophin as a trial enrichment tool in HFpEF.
Why It's Important?
The availability of the Endotrophin research prototype assay in a CLIA lab in the U.S. is a significant step for cardiovascular and renal disease research and diagnostics. Endotrophin is not just a risk marker but also a potential therapeutic target, as Mendelian randomization studies link it causally to coronary artery disease and knock-out models show protection against kidney fibrosis. For U.S. healthcare, this assay could enhance the ability to identify patients at higher risk for cardio-renal syndrome, leading to earlier interventions and more personalized treatment strategies. The FDA's support for its use as a trial enrichment tool in HFpEF suggests its potential to streamline clinical trials, making drug development more efficient and bringing new therapies to patients faster. This development could ultimately improve patient outcomes and reduce the burden of these chronic diseases in the U.S.
What's Next?
The availability of the Endotrophin research prototype assay at Nordic Bioscience's CLIA lab will facilitate further research into its role in cardio-kidney-metabolic diseases. This will likely lead to more studies exploring Endotrophin as both a diagnostic biomarker and a therapeutic target. The ongoing research, supported by the FDA's letter of support, aims to solidify its utility in clinical trials, particularly for patient stratification in HFpEF. Future steps may include the development of a CE-marked or FDA-approved diagnostic test, which would enable broader clinical use. The collaboration between Roche Diagnostics and Nordic Bioscience is expected to continue, potentially yielding more advanced biomarkers for complex diseases.
Beyond the Headlines
The emergence of Endotrophin as a significant biomarker and potential therapeutic target highlights a broader trend in medicine towards understanding the intricate connections between different organ systems, particularly in cardio-renal-metabolic health. This 'systems biology' approach moves beyond treating isolated symptoms to addressing underlying biological pathways. The identification of CD44 as the Endotrophin receptor opens avenues for targeted drug development, potentially leading to novel therapies that modulate this pathway. This also underscores the increasing importance of biomarker-driven drug development, where specific biological indicators guide both diagnosis and treatment. The ethical implications include ensuring equitable access to advanced diagnostic tools and therapies, and the responsible use of biomarkers in clinical decision-making to avoid over-diagnosis or unnecessary interventions.













